Table 2.
Characteristics of participants studied in the INNOTEST comparison to amyloid PiB PET binding
| Multi-run INNOTEST assay run date | All | DEC 2003-SEP 2009 | OCT 2009–NOV 2012 | MAR 2013-Feb 2015 | MAR 2013-FEB 2015 New INNOTEST subset | ||||
|---|---|---|---|---|---|---|---|---|---|
| Amyloid PiB PET status‡ | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | |
| n= | 388 | 105 | 28 | 80 | 40 | 101 | 34 | 25 | 10 |
| CDR 0/0.5/1/2/3 (n)# | 361/25/1/1/0 | 98/7/0/0/0 | 18/9/0/1/0 | 78/2/0/0/0 | 35/5/0/0/0 | 100/0/1/0/0 | 32/2/0/0/0 | 25/0/0/0/0 | 10/0/0/0/0 |
| Age at LP (years)† | 67.1 ± 9.4 | 69.9 ± 8.2 | 72.1 ± 7.2 ** | 62.0 ± 8.7 | 71.9 ± 7.8 **** | 65.6 ± 8.3 | 73.1 ± 6.3 **** | 66.1 ± 6.2 | 72.7 ± 4.8 ** |
| Gender (% female) | 59% | 72% | 50% * | 63% | 45% | 53% | 44% | 56% | 60% |
| APOE ε4 frequency | 0.20 | 0.16 | 0.41 **** | 0.14 | 0.34 *** | 0.14 | 0.37 ** | 0.25 | 0.28 |
| Multi-run Aβ42 (pg/ml)† | 702 ± 301 | 654 ± 237 | 365 ± 115 **** | 790 ± 232 | 431 ± 174 **** | 945 ± 283 | 519 ± 196 **** | 1156 ± 323 | 654 ± 169 **** |
| Multi-run Tau (pg/ml)† | 308 ± 216 | 245 ± 110 | 466 ± 192 **** | 214 ± 91 | 515 ± 417 **** | 272 ± 126 | 465 ± 260 **** | 271 ± 91 | 498 ± 306 * |
| Multi-run pTau (pg/ml)† | 58 ± 30 | 48 ± 18 | 74 ± 24 **** | 50 ± 29 | 84 ± 39 **** | 51 ± 22 | 81 ± 36 **** | 52 ± 18 | 98 ± 43 *** |
‡
A mean cortical standardized uptake value ratio (SUVR) > 1.42 was considered positive;
#
Clinical Dementia Rating (CDR): cognitively normal 0, very mild dementia 0.5, mild dementia 1, moderate dementia 2, severe dementia 3;
†
mean ± standard deviation; Comparisons are between amyloid PiB PET negative and positive groups. Student’s T-tests were performed on continuous data and Chi square tests were performed on categorical data.
*
p<0.05,
**
p<0.01,
***
p<0.001,
****
p<0.0001